Board

Jan-Eric Österlund has worked most of his life in private equity and management buy-outs with a focus towards life science.  He has been director or chairman in companies quoted on the stock exchanges in USA, Canada, Switzerland and Sweden, and in numerous private companies within life sciences, finance, pulp & paper industries and engineering. Jan-Eric is board member of Dicot AB, a life science company quoted on Nasdaq First North. He is based in England.

Elected: January 2024 (previous 2023, 2012–2018)

Year of birth: 1945

Holdings*:
790,000 shares, 50,000 warrants serie TO1, 50,000 warrants serie TO2

Independent in relation to the company and its management: Yes

Independent in relation to larger shareholders: Yes

*Own or related natural or legal person holding shares and other financial instruments in the company. Holdings as of July 31, 2025.

Dr. Herrera is an oncologist / hematologist that has contributed directly to the worldwide registration of, among others, the cytostatic oxaliplatin. Oxaliplatin in combination with fluorouracil and leucovorin constitute one of today’s basic regimens, FOLFOX, in treatment of colorectal cancer. Currently Dr. Herrera operates as a Senior Consultant within the field of Oncology. Prior to this Dr. Herrera held the position of Vice President of Global Oncology Business Strategy and Development at Sanofi and before that he was Head of Global Oncology Franchise at Sanofi. Dr. Herrera has also served as Chairman of Chiron Therapeutics Europe and as Managing Director of Pierre Fabre Oncology Laboratories. Dr. Herrera is part of the Supervisory Board of, among others; IDDI, Nanobiotix, PDCline Pharma, Gustave Roussy-Transfert and Arcad Foundation.

Elected: January 2024 (previous 2018-2023)

Year of birth: 1950

Holdings*:
0 shares, 0 warrants

Independent in relation to the company and its management: Yes

Independent in relation to larger shareholders: Yes

*Own or related natural or legal person holding shares and other financial instruments in the company. Holdings as of July 31, 2025.

Dr. Helena Taflin is associated professor in surgery working in the section for liver surgery at the Transplant Center at Sahlgrenska University Hospital and is also head of the Clinical Trial Unit. Helena received her PhD in 2014 in a thesis regarding folate metabolism in colorectal cancer and has continued to conduct clinical studies in this subject. She is a member of several boards, including the Swedish Surgical Association.

Elected: January 2024

Year of birth: 1973

Holdings*:
250,000 shares, 0 warrants

Independent in relation to the company and its management: Yes

Independent in relation to larger shareholders: Yes

*Own or related natural or legal person holding shares and other financial instruments in the company. Holdings as of July 31, 2025.

Lars Lind founded Isofol as a representative of Yield Life AB together with Bengt Gustavsson and was its chairman until 2012. He was then a member of the board until 2018 and has since alternately been chairman or member of the nomination committee from 2020. Lars has extensive experience in business development both as a company manager, board member and investor.

Elected: January 2024 (previous 2012-2018)

Year of birth: 1941

Holdings*:
559,102 shares, 30,448 warrants serie TO1, 30,448 warrants serie TO2

Independent in relation to the company and its management: Yes

Independent in relation to larger shareholders: Yes

*Own or related natural or legal person holding shares and other financial instruments in the company. Holdings as of July 31, 2025.

Dr Sten Nilsson is a professor emeritus in oncology at Karolinska Institutet, Solna. He is a specialist in oncology and in nuclear medicine. Sten Nilsson was head of the urology cancer group at Uppsala University Hospital and at Radiumhemmet, Karolinska University Hospital, for several years and for the Oncology Clinic, Radiumhemmet, Karolinska University Hospital, from 2006 to 2008. Sten Nilsson is leading his prostate cancer research program at CancerCentrum Karolinska (CCK) and BioClinicum, Karolinska Institutet, focusing on the development of novel cancer medicines. He has previously been president of the Swedish Society of Oncology, the Swedish Association of Urological Oncology, and the Swedish Association of Nuclear Medicine. Sten Nilsson is one of the founders and main shareholders of Dextech Medical and the chairman of the Rhenman & Partners Scientific Advisory Board.

Elected: January 2024

Year of birth: 1948

Holdings*:
5 165 aktier, 688 teckningsoptioner serie TO1, 688 teckningsoptioner serie TO2

Independent in relation to the company and its management: Yes

Independent in relation to larger shareholders: Yes

*Own or related natural or legal person holding shares and other financial instruments in the company. Holdings as of July 31, 2025.